Annovis Bio Secures US Patent for Buntanetap in Nerve Injury Treatment

Annovis Bio Inc., a company in the late stages of clinical drug development focused on innovative therapies for neurodegenerative disorders like Alzheimer’s disease (AD) and Parkinson’s disease (PD), revealed that it received the US patent for techniques related to the treatment and prevention of acute brain or nerve injuries with buntanetap.

This recently granted patent is founded on buntanetap’s capacity to diminish neurotoxicity and alleviate neurodegenerative processes, which may be relevant to conditions like stroke, ischemia, traumatic brain injury, microinfarcts, and various other types of acute injuries. The patent has been issued in the EU, Japan, and globally. Following this recent approval in the US, the biotech company now possesses worldwide protection for the application of buntanetap in addressing acute neurodegenerative conditions.

“Nerve cells are inherently delicate and susceptible to structural damage upon physical impact. Buntanetap works by targeting the neurotoxic pathways that contribute to this damage, providing a potential path to protect and restore neuronal health,” commented Maria Maccecchini, Ph.D., founder, president and CEO of Annovis. “We are proud to add this patent to our growing intellectual property portfolio, further expanding the possible applications of buntanetap beyond its primary indications such as Alzheimer’s and Parkinson’s diseases.”

The patent was granted by the US Patent and Trademark Office (USPTO) on January 2, 2025, with the publication number US-2025-0000846-A1.